The study of clinical application of DC-CIK combined with chemotherapy on colon cancer

Objective:To evaluate the clinical effect and variation of immune function of dendritic cell-cytokine induced killers(DC-CIK) combined with chemotherapy on colon cancer.Methods:A total of 40 patients with colon cancer were randomly divided into two groups: 20 in chemotherapy group,received chemotherapy alone(Oxaliplatin + CF + 5-FU).20 in combined therapy group,received DC-CIK combined with chemotherapy(Oxaliplatin + CF + 5-FU).The local recurrence rates,survival rates,immune function and side effects were compared between the two groups.The percentases of T cell subsets were detected by flow cytometry,the level of cytokines was detected by enzyme-linked immuno sorbent assay(ELISA).Moreover,the safety of DC-CIK immunization therapy was assessed.Results:The local recurrence rate was 5% in chemotherapy group and 35% in combined therapy group(P0.05),whereas the 1,2-year survival rates of the two groups were showing no significant difference.After therapy in chemotherapy group,the percentage of CD8+ was higher,the ration of CD4+/CD8+was lower and the level of IL-6 was higher(P0.05);after therapy in combined therapy group,the percentage of CD4+,CD16+CD56+,the ration of CD4+/CD8+were higher,the percentage of CD4+CD25+was lower and the level of IFN-γ was higher(P0.05).The combined therapy group had less side effects(including gastrointestinal reaction and peripheral nerve toxicity) compared with the chemotherapy group(P0.05).In the course of DC-CIK cells feedback,obvious adverse reaction didn't appear.Conclusion:DC-CIK combined with chemotherapy in treatment of colon cancer is safe and effective,and it maybe depress the tumor recurrence and metastasis,improve the patients' immune function,reduce adverse effects and have higher security attributes.